SCHEMBL1009837

SCHEMBL1009837

CC(C)(Oc1cccc(CNCC(Oc2ccccc2)c2nc3ccccc3o2)c1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 16/20 0.52
PPARG P37231 14/20 0.52
PPARD Q03181 9/20 0.52
P2RY14 Q15391 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009987 0.95 PPARA (0.48) PPARAPPARGPPARD
SCHEMBL1012094 0.93 PPARA (0.50) PPARAPPARGPPARDP2RY14
SCHEMBL1009457 0.91 PPARA (0.51) PPARAPPARGPPARDP2RY14
SCHEMBL1009685 0.91 PPARG (0.54) PPARAPPARGPPARDP2RY14
SCHEMBL1011109 0.91 PPARA (0.50) PPARAPPARGPPARD
SCHEMBL1010612 0.90 PPARA (0.56) PPARAPPARGPPARD
SCHEMBL1012086 0.87 PPARA (0.47) PPARAPPARGPPARD
SCHEMBL1012221 0.87 PPARA (0.47) PPARAPPARGPPARDP2RY14
SCHEMBL1009638 0.87 PPARG (0.50) PPARAPPARGPPARD
SCHEMBL1010688 0.86 PPARD (0.52) PPARAPPARGPPARDP2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.